Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort

Fig. 1

Levels of amyloid plasma biomarkers measured by IPMS and according to diagnosis. A42/40 ratio is decreased in the AD group relative to MCI and SCI with an effect of group and APOE ε4 status. B IPMS-Shim composite score is significantly greater in AD relative to both MCI and SCI groups with an effect of group and APOE ε4 status. C The Aβ42/40 ratio evaluated with IPMS-Shim is decreased in AD relative to NDD and OND groups with an effect of diagnosis and age. D The IPMS-Shim composite score is increased in AD relative to both groups with an effect of diagnosis and age. Plasma cutoffs, 0.017 for IPMS-Shim-Aβ42/40 and 4.6 for IPMS composite score, are represented with dashed lines. Results are boxplot, and mean ± SD are indicated below, n = 12–73. ANCOVA with diagnosis, age, and APOE ε4 status as factors followed by multiple comparisons of means using Tukey contrasts and diagnosis as a factor; ***p < 0.001, **p < 0.01

Back to article page